Literature DB >> 25582494

How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.

A Nijdam1, K Kurnik2, R Liesner3, R Ljung4, B Nolan5, P Petrini6, K Fischer1,7.   

Abstract

To facilitate early prophylaxis, step-up regimens starting prophylaxis with infusions 1× week(-1) were introduced. Choice of initial regimen may affect outcome. This study aims to classify initial prophylactic regimens and compare them on short-term outcome. From the 'European Paediatric Network for Haemophilia Management' (PedNet) registry, patients with severe haemophilia A without inhibitors, born 2000-2012, receiving prophylaxis were included. Treatment centres were classified according to the initial frequency of prophylactic infusions and the age at reaching infusions ≥3× week(-1) . Bleeding, and central venous access device (CVAD) use were compared at age 4 years. In 21 centres with 363 patients, three regimens were identified: (i) start prophylaxis with ≥3× week(-1) infusions before age three (full: 19% of centres, 18% of patients); (ii) start 1-2× week(-1) , increasing frequency as soon as possible (asap), reaching ≥3× week(-1) before age three (43% of centres, 36% of patients); (iii) start 1-2× week(-1) , increasing frequency according to bleeding (phenotype), reaching ≥3× week(-1) after age three (38% of centres, 46% of patients). Prophylaxis was started at median 1.2 years on the full and asap regimen vs 1.8 years on the phenotype regimen. Complete prevention of joint bleeds was most effective on the full regimen (32% full vs. 27% asap and 8% phenotype), though at the cost of using most CVADs (88% full vs. 34% asap and 22% phenotype). The three prophylaxis regimens identified had different effects on early bleeding and CVAD use. This classification provides the first step towards establishing the optimum prophylactic regimen.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  bleeding; central venous catheters; children; haemophilia A; prophylaxis; step-up regimen

Mesh:

Substances:

Year:  2015        PMID: 25582494     DOI: 10.1111/hae.12613

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Authors:  Annarita Tagliaferri; Annalisa Matichecchia; Gianna F Rivolta; Federica Riccardi; Gabriele Quintavalle; Anna Benegiamo; Rossana Rossi; Antonio Coppola
Journal:  Blood Transfus       Date:  2019-11-04       Impact factor: 3.443

2.  Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics.

Authors:  Donna M DiMichele
Journal:  Hemasphere       Date:  2018-10-02

3.  Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.

Authors:  Antonio Coppola; Massimo Franchini; Giovanni Pappagallo; Alessandra Borchiellini; Raimondo De Cristofaro; Angelo Claudio Molinari; Rita Carlotta Santoro; Cristina Santoro; Annarita Tagliaferri
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.